Stock chart
Analyses on Elron (4)
- March 18, 2026March 18, 2026
- Follow-up
Elron and Axonius: How Much of the Cynerio Exit Really Became Accessible Value?
The Cynerio transaction created a new meaningful asset for Elron, but it did not materially shorten the path to cash: the consideration became a $14.8 million private Axonius holding inside RDC, so the value created is much larger than the value already accessible to Elron share…
- Follow-up
Elron and RDC: What Really Changes if the Defense-Tech M&A Strategy Is Approved
If RDC's M&A strategy is approved, Elron will be trying to move from a minority-investment model toward control and growth in defense tech, a shift that could improve value capture per success but also raise the need for capital, approvals, and shareholder patience.
- Follow-up
Elron and CartiHeal: How Close Is the Contingent Consideration to Cash?
The CartiHeal contingent consideration is a meaningful asset for Elron, but as of year-end 2025 it is still a milestone-driven, assumption-sensitive claim rather than value that should be treated as near-cash.
Elron 2025: Value Has Been Created, but the Test Has Shifted to Liquidity and Allocation
Elron proved in 2025 that it can monetize assets and return capital, but the core thesis has shifted to how much of the remaining portfolio value is actually liquid and how management allocates that value between reinvestment, acquisitions, and shareholder returns.
